An in-depth analysis of the effect of ruxolitinib ointment in the treatment of atopic dermatitis

Ruxolitinib ointment (Opzelura), as an innovative Januskinase (JAK) inhibitor, is gradually becoming the preferred option for the treatment of inflammatory skin diseases such as atopic dermatitis (AD). Its excellent performance in clinical trials, especially in the treatment of patients with moderate to severe atopic dermatitis, has demonstrated significant therapeutic effects.

1.Clinical trials verify efficacy

The efficacy of ruxolitinib ointment has been fully verified in a number of rigorously designed clinical trials. Among them, the TRuE-AD series of trials (including TRuE-AD1 and TRuE-AD2) serve as the key < /span>Phase III clinical trials included more than 1200 patients 12 years old and above with moderate to severe atopic dermatitis. These patients have extensive skin lesions, typically ranging from 3% to 20%, and have previously responded poorly to other topical treatments.

In the trial, patients were randomly assigned to receive ruxolitinib ointment at concentrations of 0.75% or 1.5%, or placebo, twice daily for 8 weeks. The main efficacy evaluation indicators focus on EASI-75 (eczema area and severity index improvement 75% or above) and

2.Significant efficacy and rapid relief

Trial results show that ruxolitinib ointment performs well in treating atopic dermatitis. More than 50%of patients who used 1.5%concentration ruxolitinib ointment were 8weeks of treatment, the improvement standard of EASI-75 was reached, while this proportion in the placebo group was only about 15%. In addition, about 40%of patients achieved 0 or 1 on the IGA score, meaning their symptoms almost completely disappeared or were greatly relieved.

Itching is a common problem faced by patients with atopic dermatitis. Ruxolitinib ointment has also shown significant results in relieving itching. In trials, patients who used ruxolitinib ointment reported significant reductions in itching, with improvements usually visible within one to two weeks of treatment. In contrast, patients in the placebo group experienced limited improvement in itch.

3. Pay equal attention to long-term efficacy and safety

In long-term follow-up studies, the efficacy of ruxolitinib ointment has been continuously verified. The patient's significant improvement in symptoms was maintained for 12 months of continued treatment, demonstrating that ruxolitinib ointment not only has short-term efficacy but also maintains a stable therapeutic effect over long-term use.

In terms of safety, clinical trial data indicate that ruxolitinib ointment is well tolerated. The vast majority of side effects are localized and mild, with the most common adverse reactions including redness, swelling and itching of the affected skin. These reactions are usually temporary and gradually subside as treatment continues. Only a few patients have reported more serious side effects, such as local infection or allergic reactions, but the incidence is extremely low.

4.Comprehensive evaluation, new treatment options

In summary, ruxolitinib ointment (Opzelura) has demonstrated excellent efficacy and safety in the treatment of atopic dermatitis. Not only does it significantly improve the appearance and symptoms of the skin, it also provides rapid relief of itching, significantly improving the patient's quality of life. Ruxolitinib ointment is undoubtedly an important treatment option for patients with moderate to severe atopic dermatitis, especially those who have not responded well to other topical treatments.

However, despite the excellent performance of ruxolitinib ointment, patients still need to follow their doctor's recommendations when using it and regularly monitor treatment effects and potential side effects. This helps ensure optimal outcomes while minimizing risks. The emergence of ruxolitinib ointment has brought new treatment hope to patients with atopic dermatitis and provided clinicians with more treatment options.